RedHill Biopharma Awarded $733K U.S. HHS BARDA Contract To Investigate Opaganib As Host-Directed Therapeutic For Ebola Virus Disease
Portfolio Pulse from Benzinga Newsdesk
RedHill Biopharma has been awarded a $733,000 contract by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to investigate Opaganib as a host-directed therapeutic for Ebola virus disease.
September 30, 2024 | 6:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RedHill Biopharma received a $733,000 contract from BARDA to study Opaganib for Ebola treatment, potentially boosting its research capabilities and market perception.
The contract from BARDA provides financial support and validation for RedHill's research on Opaganib, which could enhance its reputation and lead to future opportunities. This is likely to positively impact RDHL's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100